Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
基本信息
- 批准号:9487175
- 负责人:
- 金额:$ 33.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsApoptosisApoptoticBAY 54-9085CASP3 geneCause of DeathCell DeathCell ProliferationCell SurvivalCellsCharacteristicsCombined Modality TherapyDataDevelopmentDiagnosticDifferentiation and GrowthDiseaseDrug CombinationsDrug TargetingEventFRAP1 geneFutureGoalsGrowthIn VitroInduction of ApoptosisLigandsMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMalignant neoplasm of liverMediatingMediator of activation proteinMolecularMolecular TargetNecrosisNormal CellNuclear ReceptorsPI3K/AKTPPAR gammaPathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPoly(ADP-ribose) PolymerasesPrimary carcinoma of the liver cellsProliferatingPropertyProteinsPublishingRas/RafReportingResearchResistanceRoleSignal TransductionTNF geneTNF-related apoptosis-inducing ligandTP53 geneTestingTherapeuticToxic effectTreatment EfficacyWNT Signaling PathwayXenograft Modelbasebeta catenincancer cellcell growthcombatcombinatorialdesigneffective therapyhepatocellular carcinoma cell lineimprovedin vivoinhibitor/antagonistknock-downliver cell proliferationnext generationnoveloverexpressionpre-clinicalpublic health relevancerapid growththerapeutic developmenttroglitazone
项目摘要
DESCRIPTION (provided by applicant): The overall long-term goal of the proposed research is to design a novel and efficient therapeutic approach for treating advanced hepatocellular carcinoma (HCC). HCC is one of the most common gastrointestinal (GI) malignancies and a major cause of death worldwide, with limited available therapeutic options. Designing safe and efficient therapeutic approaches for treating this disease is thus critically important. Ligand-activated nuclear receptor PPARγ is known to regulate growth and differentiation in a variety of cancer cells, including HCC. In our earlier studies although activation of PPARγ by its ligand Troglitazone (TZD) inhibited HCC cell proliferation, it was unable to induce any apoptosis. The drugs (or combinations) which have the potential of inducing both growth arrest and apoptosis are believed to be most effective in treating advanced forms of cancer. To determine whether TZD can be utilized as a combination therapy instead, we treated HCC cells with TZD in combination with the proapoptotic agent Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Our studies indicated that TRAIL-TZD combination can induce a significant degree of apoptosis in the HCC cells compared to either drug treatment alone and was associated with a dramatic increase in the cleavage of poly (ADP-ribose) polymerase (PARP) and Caspase 3. More in-depth studies were designed to identify the molecular target of this apoptosis, in an effort to improve our understanding of the effectors involved in apoptosis resistance of HCC. These studies revealed that a complete antagonism of ß-catenin pathway is needed to sensitize HCC cells towards TRAIL-TZD-induced apoptosis. Since treatment with TZD alone antagonized ß-catenin pathway at multiple levels via novel mechanisms, and antagonism of ß-catenin promoted HCC cell apoptosis, we hypothesize that PPARγ (or TZD) via antagonizing ß-catenin pathway sensitizes HCC cells towards TRAIL, which are otherwise insensitive to TRAIL alone. The current proposal aims to validate our hypothesis utilizing both in vitro (cellular) and in vivo (xenograft) models while elucidating the mechanisms by which ß-catenin antagonizes apoptosis and PPARγ antagonizes ß-catenin. The following specific aims are proposed to achieve our goals: (1) determine the role of ß-catenin in mediating HCC cell survival and resistance, (2) determine the mechanism by which ß-catenin is modulated during apoptosis and survival of HCC and (3) determine the role of ß-catenin on HCC survival and resistance in vivo. Successful completion of the studies is expected to provide important preclinical data on the efficacy of TRAIL-TZD combination on HCC cell apoptosis and a fundamental understanding whether ß-catenin serves as a molecular target to mediate apoptotic resistance. Based on these and as part of our long-term goal, more specific next generation inhibitors of ß-catenin (with less collateral toxicity) can be designed to be utilized i combination therapies for effectively treating patients with advanced forms of HCC.
描述(由申请人提供):拟议研究的总体长期目标是设计一种治疗晚期肝细胞癌(HCC)的新型有效治疗方法。HCC是最常见的胃肠道(GI)恶性肿瘤之一,也是全球范围内死亡的主要原因,可用的治疗选择有限。因此,设计治疗这种疾病的安全有效的治疗方法至关重要。已知配体激活的核受体PPARγ调节多种癌细胞(包括HCC)的生长和分化。在我们早期的研究中,虽然其配体Troglitazone(TZD)激活PPARγ抑制HCC细胞增殖,但不能诱导任何凋亡。具有诱导生长停滞和细胞凋亡两者的潜力的药物(或组合)被认为在治疗晚期形式的癌症中最有效。为了确定TZD是否可以用作联合治疗,我们用TZD与促凋亡剂肿瘤坏死因子相关凋亡诱导配体(TRAIL)联合治疗HCC细胞。我们的研究表明,TRAIL-TZD组合可以诱导一个显着程度的细胞凋亡的肝癌细胞相比,单独的药物治疗,并与显着增加裂解的聚(ADP-核糖)聚合酶(PARP)和半胱天冬酶3。更深入的研究旨在确定这种凋亡的分子靶点,以提高我们对肝癌细胞凋亡抵抗的效应子的理解。这些研究揭示,需要β-连环蛋白途径的完全拮抗来使HCC细胞对TRAIL-TZD诱导的凋亡敏感。由于TZD单独治疗通过新的机制在多个水平上拮抗β-catenin途径,并且β-catenin的拮抗作用促进HCC细胞凋亡,我们假设PPARγ(或TZD)通过拮抗β-catenin途径使HCC细胞对TRAIL敏感,否则HCC细胞对单独的TRAIL不敏感。目前的建议旨在利用体外(细胞)和体内(异种移植)模型验证我们的假设,同时阐明β-连环蛋白拮抗细胞凋亡和PPARγ拮抗β-连环蛋白的机制。我们提出了以下具体目标来实现我们的目标:(1)确定β-连环蛋白在介导HCC细胞存活和抗性中的作用,(2)确定β-连环蛋白在HCC细胞凋亡和存活过程中的调节机制,(3)确定β-连环蛋白在体内HCC存活和抗性中的作用.这些研究的成功完成预期将提供关于TRAIL-TZD组合对HCC细胞凋亡的功效的重要临床前数据,以及对β-连环蛋白是否充当介导凋亡抗性的分子靶标的基本理解。基于这些并且作为我们长期目标的一部分,可以设计更特异性的β-连环蛋白的下一代抑制剂(具有更少的附带毒性)以用于有效治疗患有晚期形式的HCC的患者的组合疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BASABI RANA其他文献
BASABI RANA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BASABI RANA', 18)}}的其他基金
Mixed Lineage Kinase 3 and cytokine signaling axis in hepatocellular carcinoma
肝细胞癌中的混合谱系激酶 3 和细胞因子信号轴
- 批准号:
10527344 - 财政年份:2021
- 资助金额:
$ 33.18万 - 项目类别:
Mixed Lineage Kinase 3 and cytokine signaling axis in hepatocellular carcinoma
肝细胞癌中的混合谱系激酶 3 和细胞因子信号轴
- 批准号:
10365639 - 财政年份:2021
- 资助金额:
$ 33.18万 - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
9032316 - 财政年份:2016
- 资助金额:
$ 33.18万 - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
10038787 - 财政年份:2016
- 资助金额:
$ 33.18万 - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
10324547 - 财政年份:2016
- 资助金额:
$ 33.18万 - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
9256218 - 财政年份:2016
- 资助金额:
$ 33.18万 - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
8854052 - 财政年份:2014
- 资助金额:
$ 33.18万 - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
8694742 - 财政年份:2014
- 资助金额:
$ 33.18万 - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
9190200 - 财政年份:2014
- 资助金额:
$ 33.18万 - 项目类别:
Molecular Mechanisms of Gastrin Mediated Pathways in Gastric Cancer Cells
胃癌细胞胃泌素介导途径的分子机制
- 批准号:
8242624 - 财政年份:2011
- 资助金额:
$ 33.18万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10596657 - 财政年份:2021
- 资助金额:
$ 33.18万 - 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10417219 - 财政年份:2021
- 资助金额:
$ 33.18万 - 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2015
- 资助金额:
$ 33.18万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2014
- 资助金额:
$ 33.18万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
- 批准号:
nhmrc : 1059331 - 财政年份:2014
- 资助金额:
$ 33.18万 - 项目类别:
Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2013
- 资助金额:
$ 33.18万 - 项目类别:
Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
- 批准号:
251802 - 财政年份:2012
- 资助金额:
$ 33.18万 - 项目类别:
Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
- 批准号:
191299 - 财政年份:2009
- 资助金额:
$ 33.18万 - 项目类别:
Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
8075522 - 财政年份:2009
- 资助金额:
$ 33.18万 - 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
7676912 - 财政年份:2009
- 资助金额:
$ 33.18万 - 项目类别:














{{item.name}}会员




